Versican is a potential therapeutic target in docetaxel-resistant prostate cancer

In the current study, we investigated a combination of docetaxel and thalidomide (DT therapy) in castration-resistant prostate cancer (CRPC) patients. We identified marker genes that predict the effect of DT therapy. Using an androgen-insensitive PC3 cell line, we established a docetaxel-resistant P...

Descripción completa

Detalles Bibliográficos
Autores principales: Arichi, Naoko, Mitsui, Yozo, Hiraki, Miho, Nakamura, Sigenobu, Hiraoka, Takeo, Sumura, Masahiro, Hirata, Hiroshi, Tanaka, Yuichiro, Dahiya, Rajvir, Yasumoto, Hiroaki, Shiina, Hiroaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381710/
https://www.ncbi.nlm.nih.gov/pubmed/25859560

Ejemplares similares

Ejemplares similares